Palonosetron

— THERAPEUTIC CATEGORIES —
  • Nausea

Palonosetron Generic Name & Formulations

General Description

Palonosetron (as HCl) 0.075mg/1.5mL, 0.25mg/5mL; IV inj; contains mannitol.

Pharmacological Class

Selective 5-HT3 receptor antagonist.

How Supplied

Contact supplier

Palonosetron Indications

Indications

Prevention of acute and delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of highly emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. Prevention of post-op nausea and vomiting for up to 24hrs after surgery in adults.

Palonosetron Dosage and Administration

Adult

≥17yrs: give 30mins prior to chemotherapy. 0.25mg IV as a single-dose over 30secs. Post-op: give immediately before anesthesia induction. 0.075mg IV over 10secs.

Children

<1 month: not established. 1 month–<17yrs: give 30mins prior to chemotherapy. 0.02mg/kg IV as a single-dose over 15mins; max 1.5mg/dose.

Palonosetron Contraindications

Not Applicable

Palonosetron Boxed Warnings

Not Applicable

Palonosetron Warnings/Precautions

Warnings/Precautions

Discontinue and treat if hypersensitivity reactions occur; do not reinitiate. Monitor for serotonin syndrome; discontinue and treat if occurs. Pregnancy. Nursing mothers.

Palonosetron Pharmacokinetics

See Literature

Palonosetron Interactions

Interactions

Increased risk of serotonin syndrome when concomitant with other serotonergic drugs (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue).

Palonosetron Adverse Reactions

Adverse Reactions

Headache, constipation, bradycardia, QT prolongation, diarrhea, dizziness, tachycardia, hypotension.

Palonosetron Clinical Trials

See Literature

Palonosetron Note

Notes

Formerly known under the brand name Aloxi.

Palonosetron Patient Counseling

See Literature